Eagle to acquire Arsia Therapeutics | Chemical & Engineering News
Volume 94 Issue 46 | p. 15 | Concentrates
Issue Date: November 21, 2016

Eagle to acquire Arsia Therapeutics

Department: Business
Keywords: drug delivery, biosimilars, Langer, MIT, biologics

Seeking to enter the biologics space, Eagle Pharmaceuticals will pay $30 million to acquire Arsia Therapeutics. Eagle may also pay up to $48 million more in milestone payments. Founded in 2013 by MIT professors Robert Langer and Alexander Klibanov, Arsia has technology for formulating and delivering proteins subcutaneously at high concentrations. Eagle plans to use it to develop biosimilars. It will also set up a Biologics Innovation Center in Arsia’s headquarters city of Cambridge, Mass.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment